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Schizophrenia is a life-long disorder, usually starting at early
adulthood and consisting of remitting or chronic psychosis and
functional decline.
There is ample evidence that immune processes play a role in
schizophrenia.1–4 More than 20 different auto-antibodies are at
elevated levels in patients with schizophrenia as compared to
controls.5 Autoimmune diseases (AID), such as thyrotoxicosis,
celiac disease, acquired hemolytic anaemia, interstitial cystitis and
Sjögren's syndrome, but also atopic diseases, have higher
prevalence rates among patients with schizophrenia.6,7 The
strongest genetic association with schizophrenia is found in the
MHC genes, including loci that inﬂuence immune responses.8
Further evidence for an autoimmune component comes from the
lower incidence of schizophrenia in men who used glucocorticos-
teroids for somatic diseases (odds ratio 0.52).9 It is unclear if
immune processes play a key role in all patients with schizo-
phrenia, or only in ~ 30–40% of them.10,11
A common characteristic of AID12 and severe allergies13 is their
favourable response to immune ablation and rescue with SCT.
Accordingly, we (IES and DWvB) searched for transplant cases
suffering from coincident schizophrenia.14,15 No such cases had
been discovered, but one of us (GT) retrieved the history of a
patient who developed severe psychosis after receiving a BM
transplant from his schizophrenic brother.
The patient (born 1940) had a blank psychiatric history. He was
retired, married and had two adult children. At the age of 67 he
developed fatigue and skin ecchymoses, and he was diagnosed
with chronic lymphocytic leukemia (CLL) and bone marrow
aplasia, requiring weekly blood transfusions. Chemotherapy (two
courses of CY), and treatment with cyclosporin A, rituximab and
prednisolone did not improve his CLL/aplastic anemia. In 2007 he
received an allogeneic peripheral blood SCT from one of his
brothers, who was the only HLA-matched family member. This
brother (born 1952) had schizophrenia since early adulthood and
he required treatment with multiple antipsychotic agents. No
other ﬁrst-degree relatives suffered from schizophrenia. The donor
also had a history of Lyme disease 8 years before. Serology
showed positive IgG and negative IgM for Lyme disease, and PCR
was negative for Borrelia burgdorferi DNA, consistent with inactive
prior infection. The donor used doxycycline 100 mg twice daily,
starting 4 days before the stem cell collection, as a safety measure
to prevent transmission. The patient was conditioned with
ﬂudarabine and CY, followed by an infusion of 5.0 × 106 CD34+
cells/kg from the peripheral blood of his brother. Tacrolimus was
administered to prevent GVHD. He never received steroids, and
did not develop graft-vs-host reactions. He had complete
hematologic recovery and reached full hematopoietic chimerism
(497% donor cells 4 weeks after SCT). We tapered off tacrolimus
4 months after the SCT, because of decreasing blood counts. A
few weeks later, when off tacrolimus, he developed acute
psychotic symptoms: frequent hallucinations (running commen-
tary and threatening voices), bizarre and non-bizarre delusions,
and thought broadcasting with clear consciousness. Insight and
judgment were poor. He described his mood as ‘angry’, with a ﬂat
affect. When he developed suicidal and homicidal ideation, he was
admitted to a psychiatric clinic. Neurological evaluation, magnetic
resonance imaging and electroencephalography revealed no
abnormalities. Extensive medical work-up did not reveal metabolic
disorders, underlying infections and neoplasms. Results of lumbar
puncture were normal, and screenings for viruses (including
Herpes Simplex Virus and Human Herper Virus-6), bacteria, fungi
and Lyme disease were all unremarkable. He was treated with
risperidone 3mg and citalopram 20mg, unsuccessfully. Under the
working diagnosis of delirium, all medications were discontinued and
haloperidol 1mg was administered, which was not helpful either.
The patient’s family decided for comfort care only and the
patient was lost to follow-up. He died in 2010, of unknown cause.
The following differential diagnoses were considered and
dismissed:
Delirium: Acute onset of psychotic symptoms in a 68-year-old
man after somatic disease. However, the 4-month interval
between transplantation and onset of psychosis is atypical.
Furthermore, discontinuation of all medication did not improve
his condition, nor could any somatic disorder be identiﬁed.
Endogenous schizophrenia: The patient was genetically predis-
posed to schizophrenia, given his brother had this disease.
However, acute onset at the age of 68 is rare,16 especially in
males.17 Age of onset is strongly correlated among affected
siblings, and differences in onset of more than 10 years are very
rare.18
Tick-borne infection transmitted through stem cells: The stem cell
donor had Lyme disease 8 years earlier. Transfer of tick-borne
pathogens might have caused psychotic symptoms. However, the
donor was Borrelia IgM and PCR negative and received
doxycycline before stem cell extraction.
Therefore, adoptive transfer of schizophrenia is the most
appealing etiology, not only by exclusion, but also in view of
the increasing evidence that some forms of schizophrenia have an
autoimmune origin. Although the transplanted patient fulﬁlls
these criteria, a formal diagnosis was never made given his very
unusual age of onset and potential relation to the SCT.
Adoptive transfer of AIDs seems to be rare, as we are aware of
only 21 cases reported so far among ~ 200 000 long-term survivors
of allogeneic SCTs. Stem cell donors are routinely subjected to
complete medical examination; therefore chances are small that
AID is overlooked. The 21 cases include thyroiditis (10 cases),19
vitiligo (3),20–22 psoriasis (2),23,24 type I diabetes mellitus (2),25
celiac disease (1),26 thrombocytopenia (1),27 polyglandular
syndrome type II (1)22 and systemic lupus erythematosus (1).28
Moreover, not only AIDs may be transferred by SCT but also other
immune diseases, such as allergies.13 Adoptive transfer of AIDs
and allergies is thought to be mediated by transfer of donor
lymphocytes. This suggests that the subform of schizophrenia in
the patient was mediated by lymphocytes.
Based on this single case report, we obviously cannot prove an
immune pathogenesis of schizophrenia. However, the report
supports the hypothesis of immunological involvement in
schizophrenia pathogenesis and we suggest that physicians and
patients involved in SCT take into consideration the possibility
that schizophrenia may be transmitted by the transplant.
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Taking it one step further, coexisting schizophrenia might not
per se be considered as a contraindication in patients with
standard transplant indications, but rather as an opportunity for
inducing remission of the psychotic process and as a potential
area of research.
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